Condition: AML (Acute Myeloid Leukemia) · Glioma · Cholangiocarcinoma · Sponsor: Rigel Pharmaceuticals
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
This description comes directly from the study's public registry record.
Kay Patel · (650) 624-1100 · kpatel@rigel.com
Jill DeFratis · (650) 624-1100 · jdefratis@rigel.com
Always discuss trial participation with your own doctor first.
| UCI Irvine Health | Orange, California, United States | Recruiting |
| New York Presbyterian Hospital-Columbia University Medical Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07486713